key: cord-0824602-xzl23c52 authors: Prévost, Jérémie; Gasser, Romain; Beaudoin-Bussières, Guillaume; Richard, Jonathan; Duerr, Ralf; Laumaea, Annemarie; Anand, Sai Priya; Goyette, Guillaume; Benlarbi, Mehdi; Ding, Shilei; Medjahed, Halima; Lewin, Antoine; Perreault, Josée; Tremblay, Tony; Gendron-Lepage, Gabrielle; Gauthier, Nicolas; Carrier, Marc; Marcoux, Diane; Piché, Alain; Lavoie, Myriam; Benoit, Alexandre; Loungnarath, Vilayvong; Brochu, Gino; Haddad, Elie; Stacey, Hannah D.; Miller, Matthew S.; Desforges, Marc; Talbot, Pierre J.; Gould Maule, Graham T.; Côté, Marceline; Therrien, Christian; Serhir, Bouchra; Bazin, Renée; Roger, Michel; Finzi, Andrés title: Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike date: 2020-07-30 journal: bioRxiv DOI: 10.1101/2020.06.08.140244 sha: df18458ca2795912e2c9b823167e187d06857106 doc_id: 824602 cord_uid: xzl23c52 The SARS-CoV-2 virus is responsible for the current worldwide coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoprotein of SARS-CoV-2 mediates viral entry and is the main target for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic and public health interventions. Here we performed a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against the SARS-CoV-2 Spike. The vast majority of infected individuals elicited anti-Spike antibodies within 2 weeks after the onset of symptoms. The levels of receptor-binding domain (RBD)-specific IgG persisted overtime, while the levels of anti-RBD IgM decreased after symptoms resolution. Some of the elicited antibodies cross-reacted with other human coronaviruses in a genus-restrictive manner. While most of individuals developed neutralizing antibodies within the first two weeks of infection, the level of neutralizing activity was significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection. neutralization was observed against pseudoparticles expressing VSV-G. The capacity to 138 neutralize SARS-CoV-2 S-pseudotyped particles significantly correlated with the presence of 139 RBD-specific IgG/IgM and anti-S antibodies ( Figure S4 ). While the percentage of patients 140 eliciting neutralizing antibodies against SARS-CoV-2 Spike remained relatively stable 2 weeks 141 after disease symptom onset (T2, T3, T4 and Convalescent patients), neutralizing antibody titers 142 significantly decreased after 1 month of infection (T4) or after the complete resolution of 143 symptoms as observed in the convalescent patients ( Figure 3G and 3H). Similarly to specific IgM, levels of RBD-specific IgA were also found to peak at T2 and decrease over time. CoV-2) were found to have stronger antibody responses and were more inclined to present 174 respiratory symptoms ( Figure S6 ). 175 176 This study helps to better understand the kinetics and persistence of humoral responses 177 directed against SARS-CoV-2 ( Figure 1, 2 & 3) . Our results reveal that the vast majority of 178 infected individuals are able to elicit antibodies directed against SARS-CoV-2 Spike within 2 179 weeks after symptom onset and persist after the resolution of the infection. Accordingly, all 180 tested convalescent patients were found to be seropositive. FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a 284 density of 1 x 106 cells/mL at 37°C with 8 % CO2 with regular agitation (150 rpm). Cells were 285 transfected with a plasmid coding for SARS-CoV-2 S RBD or OC43 S RBD using 286 ExpiFectamine 293 transfection reagent, as directed by the manufacturer (Invitrogen). One week 287 later, cells were pelleted and discarded. Supernatants were filtered using a 0. 1 T1 F 232 451 3664 232 313 4,49 4,09 250,63 156,47 2 T1 F 232 232 1743 232 232 4,49 4,09 50,00 50,00 3 T1 M 2990 25903 12877 232 284 239,90 266,10 1739,43 4476,28 4 T1 M 831 4270 4831 232 356 17,60 35,98 50,00 78,31 5 T1 F 448 631 5852 232 372 4,49 4,61 524,38 1353,00 6 T1 F 2924 21146 4629 232 227 86,39 415,00 50,00 1211,53 7 T1 F 232 350 5471 232 311 4,49 4,09 54,67 50,00 8 T1 M 232 232 3190 232 232 4, Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 468 patient A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and 471 SARS-CoV TMPRSS2 and TMPRSS4 promote 474 SARS-CoV-2 infection of human small intestinal enterocytes Longitudinal Change of Severe Acute 476 Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural 480 Insertions at the S1/S2 Cleavage Site of the Spike Protein 9604 232 374 13,49 4,09 50,00 50,00 62 T3 M 1878 15855 7696 232 268 71,25 50,23 50,00 332,23 63 T3 M 711 10219 14607 232 494 133,50 142,70 50,00 1252,98 64 T3 M 3053 30735 7638 232 346 196,80 184,50 114,73 4258,94 65 T3 M 3770 24356 9342 232 390 85,23 24,97 681,20 4123,71 66 T3 M 3067 36647 11330 232 232 147,00 172,40 759,88 2782,42 67 T3 F 2774 23502 6692 232 333 175,20 97,95 755,29 15586,03 68 T3 F 2861 27590 9046 232 232 275,80 62,70 544,37 4444,44 69 T3 F 599 6316 2720 232